Semaglutide, the active medication in Wegovy and Ozempic, is not a decision made at a counter. Before any prescription is written, a physician goes through your medical history, your other medications, your kidney and thyroid status, and any personal or family history that would make this class of drug a poor choice. Some patients are told yes. Some are told a different approach fits them better. That determination belongs to a doctor who has examined you, not to a website.
Work schedules on this side of DeKalb County shape how the medication actually gets used. Patients on warehouse and freight shifts along the I-20 corridor, and those working in the county schools and government offices where stepping away midday is not an option, usually settle on a fixed weekly injection day. Choosing a day when you are not on your feet for ten hours can make the first few weeks easier, since appetite changes and stomach upset tend to be most noticeable early and often ease as your dose is adjusted. That is the kind of detail worth raising at your visit.
Practical matters come up too. Brand-name coverage varies considerably from one insurance plan to the next, and availability has been uneven over the past few years, so your physician will talk through what your options look like rather than assume. For patients already seeing a provider at Emory Hillandale for diabetes, blood pressure, or thyroid care, coordination matters, because a GLP-1 can require other prescriptions to be adjusted. Plan on the drive up I-285 for your initial visit and periodic follow-ups while your dose is being titrated.
About GLP-1 Semaglutide Weight Loss
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1 is a hormone the small intestine releases after eating, and it is part of how the body signals fullness to the brain. Semaglutide imitates that signal: it slows how quickly the stomach empties, blunts the hunger and food-preoccupation that make calorie restriction so hard to sustain, and helps the pancreas release insulin in response to meals. The practical effect for most patients is not willpower arriving out of nowhere. It is that the constant background pull toward food quiets down enough for real dietary changes to hold.
Under the brand name Wegovy, semaglutide is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease. It is approved for use alongside a reduced-calorie diet and increased physical activity, not as a stand-alone substitute for them. Ozempic is the same molecule approved for type 2 diabetes. In December 2025 the FDA also approved a once-daily oral form of semaglutide for weight management, the first GLP-1 pill cleared for that use, which gives physicians an option for patients who are not candidates for or not comfortable with a weekly injection. Tirzepatide, marketed as Mounjaro and Zepbound, works on both the GLP-1 and GIP receptors and is a separate medication your physician may discuss with you.
At Atlanta Medical Institute, semaglutide is prescribed as one part of physician-supervised obesity treatment rather than as a product you simply order. Our physicians have treated weight as a chronic medical condition since 2010, and that framing shapes how the medication is used: an evaluation and appropriate lab work before the first dose, a starting dose chosen for tolerability rather than speed, scheduled follow-up to adjust the plan, and attention to nutrition, protein intake, and muscle preservation throughout. Whether semaglutide is appropriate for you, and which formulation makes sense, is a medical decision your physician makes with you after reviewing your history.
How Semaglutide Works
Appetite is regulated by hormones, not by character. People carrying excess weight often have blunted satiety signaling, which is one reason conventional dieting fails so reliably over the long run: the body defends its higher weight with hunger and a slowed metabolic rate. Semaglutide acts on several of those pathways at once.
Because the medication changes how full you feel and how quickly food leaves the stomach, portion sizes usually fall on their own rather than through deliberate restriction. Most patients notice this within the first several weeks, though the degree varies a great deal from person to person and by dose.
- Acts on GLP-1 receptors in the brain regions that govern appetite and satiety
- Slows gastric emptying, so meals stay satisfying longer
- Supports glucose-dependent insulin release, which helps blood sugar control in patients with type 2 diabetes
- Reduces food-seeking behavior and, for many patients, the intrusive food thoughts often described as food noise
- Is taken as a once-weekly injection, or as a once-daily tablet in the oral form approved for weight management
Who Is a Candidate
Candidacy is determined by a medical evaluation, not by a questionnaire. Our physicians review your weight history, prior attempts at weight loss, current medications, and any conditions that make weight loss medically important, such as prediabetes, type 2 diabetes, hypertension, elevated lipids, fatty liver disease, sleep apnea, PCOS, or joint disease. Baseline labs are typically part of that workup, and thyroid, kidney, and metabolic status are reviewed before a prescription is written.
Some patients should not take semaglutide at all, and others need closer supervision or a different medication entirely. The list below covers the most common reasons a physician will steer away from it. It is not complete, which is exactly why the evaluation matters.
- Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, which are contraindications
- Prior serious hypersensitivity reaction to semaglutide or any component of the product
- Pregnancy, planning pregnancy, or breastfeeding
- History of pancreatitis, gallbladder disease, gastroparesis, or significant gastrointestinal disease
- Type 1 diabetes, or type 2 diabetes treated with insulin or a sulfonylurea, where doses may need adjusting to avoid low blood sugar
- Active diabetic retinopathy, which warrants ophthalmologic follow-up during rapid glucose improvement
- A history of an eating disorder, or a BMI below the approved thresholds
What Treatment Involves
Semaglutide is started low and increased slowly. The weekly injectable form typically begins at 0.25 mg, with increases about every four weeks as tolerated, working toward a maintenance dose that may go up to 2.4 mg. The oral form has its own titration schedule and specific instructions about taking it on an empty stomach. These schedules are a framework, not a race. If side effects appear at a given step, your physician may hold you at that dose longer or move back down, and plenty of patients do well at a dose below the maximum.
Follow-up visits are where the actual work happens. Weight, blood pressure, and relevant labs are tracked, side effects are addressed, and the dose is adjusted based on how you are responding rather than on a fixed calendar. Our physicians also use these visits to keep nutrition on track, because appetite suppression without adequate protein and resistance training tends to cost lean muscle along with fat.
Semaglutide is not a short course of treatment in the way an antibiotic is. Obesity behaves like a chronic condition, and the medication manages it while it is being taken. In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping. That is not a reason to avoid treatment; it is a reason to plan for the long term from the beginning, and to discuss maintenance strategy with your physician well before any decision to taper or stop.
Side Effects, Monitoring, and Safety
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reflux. They cluster in the first few weeks after starting and after each dose increase, and they usually ease as the body adapts. Smaller meals, slower eating, lower fat content, and adequate fluids all help. Persistent vomiting or diarrhea can cause dehydration and affect kidney function, so it should be reported rather than endured.
Less common but more serious risks carry specific warnings on the FDA label. Acute pancreatitis has been reported with GLP-1 medications; severe, persistent abdominal pain, with or without vomiting, warrants immediate medical attention and discontinuation. Gallstones and gallbladder inflammation occur more often during rapid weight loss. Semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures, and whether it does so in humans is unknown, which is the basis for the boxed warning and the contraindications noted above. Patients on insulin or sulfonylureas can experience low blood sugar and may need those doses reduced.
Two practical points get overlooked often enough to be worth stating plainly. First, because semaglutide slows gastric emptying, tell any surgeon, anesthesiologist, or proceduralist that you are taking it, since food retained in the stomach raises aspiration risk under sedation or general anesthesia. Second, tell every clinician treating you, including your primary care physician, what dose you are on. Our physicians coordinate with outside providers when that is useful, and we would rather have the full picture than manage around a gap in it.
- Report severe or persistent abdominal pain, ongoing vomiting, or signs of dehydration right away
- Tell your care team before any surgery, endoscopy, or procedure requiring sedation
- Emphasize protein intake and resistance training to help preserve lean muscle during weight loss
- Expect periodic labs and in-person follow-up rather than automatic refills
- Discuss any new or changing medications, particularly diabetes medications, with your prescribing physician
Getting Here from Lithonia
Most patients from Lithonia pick up I-20 at the Evans Mill or Panola Road exits, head west to I-285 north around the east side of the Perimeter, and come off at the Roswell Road exit a short distance from Suite 201 at 5009 Roswell Road NE; some prefer staying on I-20 to the downtown connector and taking GA-400 to the Buckhead exits instead.
5009 Roswell Road NE, Suite 201
Atlanta, GA 30342
We see patients from across Lithonia and nearby areas including Downtown Lithonia Historic District, Fairington, Swift Creek, Rogers Crossing, Klondike.
Semaglutide (GLP-1) Weight Loss in Lithonia — Frequently Asked Questions
Is semaglutide the same thing as Ozempic or Wegovy?
Semaglutide is the active medication in both. They are approved for different purposes and dosed differently, and which one, if either, fits your situation is something your physician determines after evaluating you. Both are prescription medications that require ongoing medical supervision.
Who is not a candidate for semaglutide?
Your physician will screen for several things, including a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, a history of pancreatitis, pregnancy, and certain gastrointestinal conditions. Other medications you take can matter as well. This is exactly why the evaluation comes before the prescription.
How often would I need to come to the Atlanta office?
More often at the beginning, while your dose is being adjusted and your response is being monitored, then less frequently once you are stable. Our hours are Monday through Thursday 9 to 6 and Friday 9 to 4. Call (404) 341-4819 to talk through what the schedule would look like for you.
Is semaglutide the same thing as Ozempic and Wegovy?
Semaglutide is the active medication; Ozempic and Wegovy are brand names for it. Ozempic is FDA-approved to treat type 2 diabetes, and Wegovy is FDA-approved for chronic weight management in adults who meet the BMI criteria, as well as for reducing cardiovascular risk in certain patients. A once-daily oral form of semaglutide was also approved for weight management in December 2025. Your physician will determine which product and which form fits your diagnosis and history.
How quickly will I notice a difference?
Many patients notice reduced appetite within the first few weeks, often before the scale moves much, because the starting dose is deliberately low and increases gradually. Meaningful weight change typically unfolds over months rather than weeks, and it varies considerably between individuals. We do not promise a specific number of pounds, and you should be cautious of anyone who does.
What is the difference between compounded semaglutide and the FDA-approved version?
FDA-approved semaglutide products are manufactured and tested under FDA oversight with an approved label. Compounded versions are prepared by compounding pharmacies and are not FDA-approved, reviewed for safety and effectiveness, or subject to the same manufacturing standards. Wide-scale compounding of semaglutide copies was permitted during the national shortage, but the FDA removed semaglutide from its shortage list in February 2025 and the compounding pathways narrowed considerably through 2025 and 2026. The FDA has also warned about unapproved and counterfeit GLP-1 products sold online and through unlicensed sellers. Ask any provider directly what they are prescribing and where it comes from, and discuss the differences with your physician before starting.
Do I still have to change how I eat and exercise?
Yes. Semaglutide is approved for use along with a reduced-calorie diet and increased physical activity, not in place of them. The medication makes those changes far more achievable by quieting hunger, but nutrition still determines the quality of the weight you lose. Protein intake and resistance training in particular help protect lean muscle, which is why our physicians build them into the plan rather than treating them as optional extras.
What happens if I stop taking it?
Appetite generally returns, and weight regain is common. In the STEP 1 trial extension, participants regained roughly two-thirds of the weight they had lost within a year of stopping. Obesity is a chronic condition, and semaglutide manages it while it is being taken. If you and your physician decide to stop or taper, that decision should come with a maintenance plan rather than an abrupt end to care.
How is semaglutide different from tirzepatide?
Tirzepatide, sold as Mounjaro and Zepbound, acts on both the GIP and GLP-1 receptors, while semaglutide acts on the GLP-1 receptor alone. Both are given as weekly injections and both require titration. In studies and in practice, some patients respond better to one than the other, and tolerability, medical history, coverage, and availability all factor into the choice. Anyone switching between them starts the new medication at its lowest dose regardless of the dose they were on before. Your physician will discuss which is the better fit for you.
Want the full clinical detail? Read about our Semaglutide Program program.